L A Dolak
Overview
Explore the profile of L A Dolak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Allwine D, Barbachyn M, Grega K, Dolak L, Ford C, et al.
Bioorg Med Chem
. 2001 Nov;
9(12):3243-53.
PMID: 11711300
In an effort to expand the spectrum of activity of the oxazolidinone class of antibacterial agents to include Gram-negative bacteria, a series of new carbon-carbon linked pyrazolylphenyl analogues has been...
2.
Thorarensen A, Deibel Jr M, Rohrer D, Vosters A, Yem A, Marshall V, et al.
Bioorg Med Chem Lett
. 2001 May;
11(11):1355-8.
PMID: 11378353
Peptidyl deformylase (PDF) is a metallo protease that catalyzes the removal of a formyl group from the N-termini of prokaryotic prepared polypeptides, an essential step in bacterial protein synthesis. Screening...
3.
Turner S, Strohbach J, Tommasi R, Aristoff P, Johnson P, Skulnick H, et al.
J Med Chem
. 1998 Aug;
41(18):3467-76.
PMID: 9719600
A broad screening program previously identified phenprocoumon (1) as a small molecule template for inhibition of HIV protease. Subsequent modification of this lead through iterative cycles of structure-based design led...
4.
Wishka D, Graber D, Kopta L, Olmsted R, Friis J, Hosley J, et al.
J Med Chem
. 1998 May;
41(9):1357-60.
PMID: 9554867
No abstract available.
5.
Skulnick H, Johnson P, Aristoff P, Morris J, Lovasz K, Howe W, et al.
J Med Chem
. 1997 Mar;
40(7):1149-64.
PMID: 9089336
Recently, cyclooctylpyranone derivatives with m-carboxamide substituents (e.g. 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked significant antiviral activity in cell culture. Substitution of a sulfonamide...
6.
Heier R, Dolak L, Duncan J, Hyslop D, Lipton M, Martin I, et al.
J Med Chem
. 1997 Feb;
40(5):639-46.
PMID: 9057850
The imidazoquinoline (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine [(R)-3] is a potent dopamine agonist when tested in animals but surprisingly shows very low affinity in in vitro binding assays. When incubated with mouse or monkey...
7.
Thaisrivongs S, Skulnick H, Turner S, Strohbach J, Tommasi R, Johnson P, et al.
J Med Chem
. 1996 Oct;
39(22):4349-53.
PMID: 8893827
No abstract available.
8.
Thaisrivongs S, Janakiraman M, Chong K, Tomich P, Dolak L, Turner S, et al.
J Med Chem
. 1996 Jun;
39(12):2400-10.
PMID: 8691434
The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover non-peptidic HIV protease...
9.
Althaus I, Franks K, Langley K, Kezdy F, Peterson T, Buxser S, et al.
Experientia
. 1996 Apr;
52(4):329-35.
PMID: 8620935
Few inhibitors of the RNase H function associated with the HIV-1 reverse transcriptase have been discovered to date. We observed that three novenamines, U-34445, U-35122, and U-35401, are specific inhibitors...
10.
Skulnick H, Johnson P, Howe W, Tomich P, Chong K, Watenpaugh K, et al.
J Med Chem
. 1995 Dec;
38(26):4968-71.
PMID: 8544171
No abstract available.